Von Hippel-Lindau tumor suppressor (VHL)

The Von Hippel-Lindau (VHL) tumor suppressor is a critical component of the CBC(VHL) E3 ubiquitin ligase complex, where it serves as the substrate recognition subunit [1][6]. Its primary physiological role is the oxygen-dependent degradation of hypoxia-inducible factors (HIF-1α and HIF-2α); under normoxic conditions, VHL binds to prolyl-hydroxylated HIF and marks it for proteasomal destruction, thereby maintaining cellular oxygen homeostasis [1][11]. Loss of VHL function, through germline or somatic mutations, leads to the constitutive stabilization of HIF, driving the expression of pro-angiogenic and proliferative genes such as VEGF [8][12]. This mechanism is the fundamental driver of Von Hippel-Lindau syndrome and the majority of clear cell renal cell carcinomas (ccRCC) [2][9]. In modern drug discovery, VHL has become a premier target for Targeted Protein Degradation (TPD) as a recruiter for Proteolysis-Targeting Chimeras (PROTACs). Small-molecule VHL ligands, such as VH032, are used to bridge the E3 ligase to a protein of interest, inducing its ubiquitination and subsequent degradation [3][5][7]. While direct VHL inhibitors are being explored to mimic the hypoxic response for therapeutic benefit in ischemia or anemia, the most clinically advanced approach in VHL-deficient cancers involves targeting downstream effectors like HIF-2α [2][10][13].

Other names

pVHLRCA1VHL1HRCA1Von Hippel-Lindau disease tumor suppressor

Recruitment of the CBC(VHL) E3 ubiquitin ligase complex to induce targeted protein degradation (PROTACs) or stabilization of HIF subunits via competitive inhibition of the VHL-HIF interaction [3][5][6][11].